Burden of paediatric respiratory syncytial virus disease and potential effect of different immunisation strategies: a modelling and cost-effectiveness analysis for England

BACKGROUND: Vaccines and prophylactic antibodies against respiratory syncytial virus (RSV) are in development and likely to be available in the next 5–10 years. The most efficient way to use these products when they become available is an important consideration for public health decision makers. ME...

Descripción completa

Detalles Bibliográficos
Autores principales: Cromer, Deborah, van Hoek, Albert Jan, Newall, Anthony T, Pollard, Andrew J, Jit, Mark
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier, Ltd 2017
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541134/
https://www.ncbi.nlm.nih.gov/pubmed/28804787
http://dx.doi.org/10.1016/S2468-2667(17)30103-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541134/
https://www.ncbi.nlm.nih.gov/pubmed/28804787
http://dx.doi.org/10.1016/S2468-2667(17)30103-2

Ejemplares similares